Get App

U.S. FDA panel recommends approval of Johnson & Johnson's depression drug

An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.
  • Published On Feb 13, 2019 at 12:29 PM IST
An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.

The panel voted 14-2 in favor of the drug esketamine, developed to treat major depression in patients who have not benefited from at least two different therapies, saying its benefits outweighed the risks.

One member in the panel abstained from voting on the question. Esketamine is a variation of the anesthetic ketamine, which is also abused as a recreational party drug with the street nickname Special K.
  • Published On Feb 13, 2019 at 12:29 PM IST

Comments

comment
What are your thoughts?
Comment Now Read Comment (1)

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!